Amivantamab-vmjw 50 mg/ML [Rybrevant]
RxNorm 2549736

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2549736 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: amivantamab-vmjw 50 mg/ML [Rybrevant].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Amivantamab-vmjw 50 mg/ML [Rybrevant]
AUI:12640425
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Amivantamab-vmjw 50 mg/ML [Rybrevant]
(Atom ID: 12640425)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
amivantamab-vmjw 50 MG/ML [Rybrevant]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2549736
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12640425
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2549736
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Amivantamab-vmjw Injection


Amivantamab-vmjw injection is used to treat a certain type of non-small cell lung cancer (NSCLC) that spread to other parts of the body or cannot be removed by surgery, and has worsened either during or after treatment with platinum chemotherapy medications. Amivantamab-vmjw injection is in a class of medications called bispecific antibodies. It works by helping your immune system to slow or stop the growth of cancer cells.
[Learn More]


* Please review the disclaimer below.